CINECA IRIS Institutional Research Information System

CIAMPI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.123
EU - Europa 4.713
AS - Asia 3.608
SA - Sud America 464
AF - Africa 201
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 16.119
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.931
IT - Italia 1.922
CN - Cina 1.048
SG - Singapore 1.045
DE - Germania 882
HK - Hong Kong 646
SE - Svezia 592
BR - Brasile 397
VN - Vietnam 301
GB - Regno Unito 255
BG - Bulgaria 206
AT - Austria 170
CA - Canada 150
FR - Francia 147
TR - Turchia 133
FI - Finlandia 128
RU - Federazione Russa 128
IN - India 117
CI - Costa d'Avorio 104
JP - Giappone 70
NL - Olanda 68
UA - Ucraina 61
KR - Corea 50
SN - Senegal 44
BD - Bangladesh 35
IQ - Iraq 27
MX - Messico 25
PL - Polonia 25
CH - Svizzera 22
ZA - Sudafrica 20
AR - Argentina 18
BE - Belgio 18
EE - Estonia 15
PK - Pakistan 15
SA - Arabia Saudita 15
ES - Italia 14
ID - Indonesia 14
EC - Ecuador 12
MA - Marocco 12
UZ - Uzbekistan 12
VE - Venezuela 12
TW - Taiwan 10
CZ - Repubblica Ceca 8
IR - Iran 8
AZ - Azerbaigian 7
CO - Colombia 7
IL - Israele 7
KE - Kenya 7
PH - Filippine 7
AE - Emirati Arabi Uniti 6
HU - Ungheria 6
JO - Giordania 6
RO - Romania 6
GR - Grecia 5
LT - Lituania 5
MY - Malesia 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
AU - Australia 4
BY - Bielorussia 4
CL - Cile 4
DO - Repubblica Dominicana 4
IE - Irlanda 4
PA - Panama 4
PE - Perù 4
PY - Paraguay 4
RS - Serbia 4
DZ - Algeria 3
EU - Europa 3
NG - Nigeria 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
TH - Thailandia 3
DK - Danimarca 2
EG - Egitto 2
GT - Guatemala 2
JM - Giamaica 2
LK - Sri Lanka 2
MK - Macedonia 2
OM - Oman 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
Totale 16.111
Salva come PNG Salva come JPEG
Città #
Ashburn 768
Dallas 651
Hong Kong 631
Woodbridge 593
Singapore 578
Fairfield 464
San Jose 414
Ann Arbor 393
Chandler 391
Santa Clara 377
Houston 349
Milan 299
Beijing 217
Shanghai 209
Sofia 204
Seattle 172
New York 170
Wilmington 166
Vienna 162
Cambridge 151
Los Angeles 113
Ottawa 111
Abidjan 104
Boardman 104
Pisa 99
Rome 94
Princeton 91
Ho Chi Minh City 83
Florence 79
Lawrence 75
Lauterbourg 70
Munich 69
Medford 64
Serra 63
Frankfurt am Main 62
Izmir 62
Jacksonville 59
Tokyo 59
Hefei 55
Dearborn 54
Hanoi 54
Helsinki 52
Nanjing 52
London 51
São Paulo 50
Des Moines 46
Naples 46
Seoul 45
Dakar 44
Istanbul 44
Redondo Beach 43
Council Bluffs 37
Bremen 35
San Diego 34
Bologna 33
Orem 30
Buffalo 29
Düsseldorf 25
Dong Ket 24
Tianjin 24
Redmond 21
Redwood City 21
Boulder 20
Lancaster 20
Nanchang 20
Chicago 18
Columbus 18
Turin 18
Cascina 17
Fuzhou 17
Brussels 16
Baghdad 15
Bern 15
Genoa 15
Guangzhou 15
Rio de Janeiro 15
Turku 15
Verona 15
Bengaluru 14
Boston 14
Brooklyn 14
Hangzhou 14
Ogden 14
Palermo 14
Parma 13
Toronto 13
Atlanta 12
Belo Horizonte 12
Changsha 12
Johannesburg 12
Tashkent 12
Washington 12
Jaboatão 11
Jüchen 11
Poplar 11
Trieste 11
Warsaw 11
Wuhan 11
Denver 10
Jiaxing 10
Totale 10.306
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.154
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 340
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 288
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 273
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 257
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 238
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 231
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 227
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 226
Targeted Therapy in Thyroid Cancer: State of the Art 223
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 221
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 216
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 215
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 212
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 202
BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer 197
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 196
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 195
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 193
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 192
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 191
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 187
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 184
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 182
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 182
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 176
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 174
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors 173
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 172
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 171
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 171
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 169
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 162
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 161
null 160
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 157
null 157
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization 154
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 153
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 153
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 153
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 151
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 151
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 149
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 144
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 143
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 143
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 140
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 140
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 137
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RAR{beta} mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 137
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 136
Alterations of the BRAF gene in thyroid tumors 135
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid 131
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 129
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 129
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 127
Studi in vitro del trattamento con acido retinoico di linee cellulari di carcinoma tiroideo umano anaplastico, scarsamente differenziato, follicolare e midollare 125
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 125
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 124
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas 124
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes 123
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation 123
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 123
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 120
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 119
Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis 119
HOOK3-RET: A novel type of RET/PTC rearrangement in papillary thyroid carcinoma 118
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer 114
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 112
Genetic heterogeneity of Medullary Thyroid Carcinoma 110
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 108
Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis 108
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients 101
The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma 101
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity 101
null 99
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation 99
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 96
Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes 95
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value 94
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 93
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 91
BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review 91
SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN 91
Ret Oncogene and Thyroid Carcinoma 81
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 77
null 75
null 70
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib 63
null 58
null 51
Totale 16.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.276
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021125 0 0 0 0 0 0 0 0 0 0 34 91
2021/20221.068 38 58 21 75 211 131 36 47 55 49 78 269
2022/20231.735 205 247 139 136 143 187 61 124 310 37 107 39
2023/20241.384 158 130 126 109 167 201 117 79 63 39 67 128
2024/20253.260 65 139 63 185 341 294 267 205 328 402 368 603
2025/20263.947 266 589 521 356 399 286 640 200 250 365 75 0
Totale 16.336